|
Published by: Drug and Market Development Publishing
Published: Oct. 1, 2005 - 124 Pages
Table of Contents
Chapter 1: Executive Summary
Scope of This Report
Why is hERG becoming so crucial in Drug Discovery and Development?
What are the strategic opportunities in the hERG marketplace?
Summary of hERG as a Toxicity Marker for Drug Discovery and Development
and the Associated Market Opportunity
Chapter 2: hERG—The Channel, Its Physiological Role, and
Drug Toxicity
Scope of This Chapter
Long QT Syndrome (LQTS) and Torsades de Pointes
Biology of hERG and its Role in QT Prolongation
hERG: A Promiscuous Target for Drug Interactions
Molecular Modeling of hERG: Predictive In silico Modeling for hERG Channel
Blockers and Features-Motifs of hERG Rendering it ‘Promiscuous’
Affecting the Biological Function of hERG Other than by Blocking its Channel
with Drugs
In Conclusion—hERG and Drug-induced LQTS
Chapter 3: Experimental Approaches for Screening hERG
Scope of This Chapter
What is the experimental problem that needs to be addressed?
Requirements for hERG Toxicity Screening
In vitro and in vivo Approaches to hERG Channel Screening
Chapter 4: Market Analysis of the hERG Space
Scope of This Chapter
End-User Survey: Data and Analysis
Quantitative Market Opportunity and Market Model
Chapter 5: Company Profiles
Scope of This Chapter
Aurora Biomed
AVIVA Biosciences Corporation
Cellular Dynamics International
CEREP
ChanTest
CreaCell
Cyprotex
Cytomyx Ltd.AbstractD&MD’s hERG: Technology and Market Analysis Report is the only syndicated report that comprehensively addresses the hERG market landscape. The Report details the physiology and biology of hERG as well as its role in drug toxicity. It focuses on the physiological functioning of the hERG channel, its blockade by drugs and precipitation of LQTS. In addition to describing the technical aspects of hERG, the Report presents a thorough market analysis complemented by primary data from a proprietary survey conducted on this topic by D&MD.
Get Full Details About This Report >>
|
